Azitra, Inc. (AMEX:AZTR) shares are trading higher after the company announced that the U.S. Patent and Trademark Office granted its patent application regarding the treatment of atopic dermatitis.

The Details: The patent, U.S. Patent No. 12,036,248, protects a filaggrin-secreting strain of Staphylococcus epidermidis for the treatment of atopic dermatitis.

The goal is to address diseases associated with a filaggrin deficiency, like atopic dermatitis, by delivering filaggrin directly to the skin.

"The indication addressed by the newly issued U.S. patent, atopic dermatitis, affects approximately 16.5 million people in the United States," said Aztira's COO Travis Whitfill.

Azitra also holds a U.S. patent which protects the use of the same strain for treating inflammatory skin disease. The company has sought similar patents in China and Canada.

How To Buy Azitra Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Anitra (AMEX:AZTR)'s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

AZTR Price Action: At the time of writing, Azitra shares are trading 389% higher at $7.93 per data from Benzinga Pro.

Image: Akava Photo from Pixabay